



EMA/495296/2015 Rev.1

**Update of 27 September 2018:**

The shortage affecting Cerezyme (imiglucerase) has been resolved and the below information and recommendations which were issued during the shortage no longer apply.

04 November 2013

<b>Cerezyme (imiglucerase) solution for infusion</b>	
<b>Indication</b>	Cerezyme is used for the long-term treatment of patients with Gaucher disease.
<b>Reason for shortage</b>	The supply shortage of Cerezyme began in June 2009 and was caused by a series of manufacturing problems at one of its manufacturing sites. Information issued by the EMA previously on the supply situation for Cerezyme can be found <a href="#">here</a> .
<b>Member States affected<sup>1</sup></b>	All European Union (EU) Member States.
<b>Information to healthcare professionals</b>	<ul style="list-style-type: none"><li>• Stock levels are continuing to improve, however the product supply remains vulnerable to disruption.</li><li>• Based on current stock levels, patients currently treated with Cerezyme can receive the full dose recommended in the summary of product characteristics.</li><li>• Healthcare professionals who wish to start new patients should contact the company prior to starting treatment. New patients can be started as long as existing stocks are sufficient.</li><li>• Additional advice may be available from the <a href="#">national competent authority</a>.</li><li>• Additional advice may be available from the <a href="#">national competent authority</a>.</li></ul>

<sup>1</sup> This information may change. For accurate information about the status of a medicine shortage in a particular Member State the national competent authority should be contacted.



## Cerezyme (imiglucerase) solution for infusion

### Information to patients

- Stock levels are continuing to improve, however the product supply remains vulnerable to disruption.
- For patients who are currently being treated with Cerezyme, the treating doctor will now be able to prescribe the full dose.
- New patients may now be able to receive Cerezyme.
- Patients who have any questions should speak to their doctor or pharmacist.
- Additional advice may be available from the [national competent authority](#).
- Patients may also contact [Eurordis](#), an organisation representing people with rare diseases in Europe.
- Additional advice may be available from the [national competent authority](#).